Treatment-related biomarkers in pulmonary hypertension patients on oral therapies.

Aparna C SwaminathanHongmei ZhuVictor TapsonYuliya LokhnyginaAbby PomsZach KelleherElijah GaspardKarla KennedyBrian E FeeTerry FortinS Nicholas MasonKishan ParikhTimothy J McMahon

Published in: Respiratory research (2020)

ET-1, cGMP/NTproBNP ratio, and dimethylarginines ADMA and SDMA are mediators along pathways targeted by oral PAH therapies that associate with or predict 6MWD.

Keyphrases

pulmonary hypertension
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
pulmonary artery
patient reported outcomes
protein kinase
combination therapy